

**Biochemical and Culture-Based Approaches to Identification in the Diagnostic Microbiology Laboratory**

## **Abstract**

The late 1800s through the early 1900s saw the rapid development of growth media containing various substrates, i.e. carbohydrates, to identify and differentiate microbes isolated from clinical specimens. However, during the 1950s, an evolution of diagnostic services occurred created by a growing population with access to health insurance and the subsequent requirement for quality healthcare. The utilization of miniaturized, multi-test kits provided the first significant advancement of the biochemical, growth-based approach needed to handle the increased demand for clinical services. These testing kits provided reductions in labor and material costs associated with making, maintaining, inoculating, and reading tubed and plated media, while also reducing the time required to identify microbial isolates. The trend to improve laboratory efficiency and quality continued with the incorporation of automation and computers throughout the 1970s. Automated systems greatly increased the testing capacity of laboratories by allowing the simultaneous determination of identification and antimicrobial susceptibilities from one inoculum, and by further reducing the time to identification to hours instead of days. Within just the last 10 – 15 years, development and integration of a new growth-based approach for identification has occurred in the form of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). The mass spectrometric approach provides the lowest cost per analysis and fastest time to identification after isolation of any current technique available in the microbiology laboratory. As healthcare costs and demand continue to increase, and more hospitals look to consolidate laboratories, fully automated facilities incorporating mass spectrometry for identification, along with molecular methods, will become commonplace.

## **Abbreviations**

API – Analytical Profile Index, AST – Antimicrobial Susceptibility Testing, MALDI-TOF – Matrix Assisted Laser Desorption Ionized-Time of Flight, MS – Mass Spectrometry, TTR – Time to Result, PCR – Polymerase Chain Reaction, TSI – Triple Sugar Iron

## **Index Terms**

Automation, Biochemical Test, Tube-based Tests, Culture Media, MALDI-TOF

## **Learning Outcomes**

1. Recognize different biochemical approaches to microorganism identification used in the clinical microbiology laboratory, including specific examples of tube-based, test kit, and automated methodologies.
2. Compare and contrast the advantages, disadvantages, and performance characteristics of each approach to identification, and determine the usefulness of each in addressing a specific clinical situation.
3. Identify the factors which drove the development of new biochemical technologies to address the evolving healthcare industry.

## **Introduction**

The utility of the biochemical, or metabolic, test has been on display for nearly 150 years for the isolation and identification of microorganisms causing infectious disease, due in large part to the very nature of microbial versatility. With the establishment of the germ theory of disease (1870), medical researchers were presented with a challenge to prove the link between microbe and disease. Instruction on how this could be accomplished came in the form of Koch's postulates (1882), along with contributions from other researchers, with the specific requirement that a disease-causing agent must be isolated on culture media.<sup>1</sup> Thus, what ensued was an age of great experimentation and discovery into the various growth properties of bacteria and other microbes, which was as reliant on knowledge of biochemistry as it was on standard microbiology techniques.<sup>2</sup>

## **Development and Use of Plate and Tube-Based Media for Identification**

The need to cultivate and isolate infectious bacteria or fungal organisms led researchers to explore various nutrient-rich sources for organism growth. They began with the reasonable assumption that bodily fluids, and by extension basic organic components such as protein and carbohydrates, would provide that source for growth. It was quickly observed that culture media containing blood, peptones, and even potatoes (among other ingredients) were quite effective for growing many different bacteria.<sup>2,3</sup> In the late 1800s, the ability of certain bacteria to ferment particular carbohydrates, resulting in the formation of acid and gas, was noted to be a useful differential indicator for separating out members of the Enterbacteriaceae (referred to at the time as the colon-aerogenes family) and other gram negative bacilli from clinical and environmental specimens.<sup>4-6</sup> This led to the formation of the Durham tube, MacConkey agar, and eventually triple sugar-ferrous sulfate (now TSI) media.<sup>4,7-9</sup> Other chemical reactions resulting in pH

changes were observed and by incorporating indicators in media, allowed detection of acidic and alkaline products, such as with citrate utilization<sup>10</sup> and urease production.<sup>11</sup>

From 1900 through 1950 the enzymatic versatility of bacteria was harnessed in many single-test solid, semi-solid, and liquid media where metabolic end products could be detected with the addition of a chemical reagent. Enzyme profiles through testing of nitrate reduction,<sup>12</sup> indole formation,<sup>13</sup> oxidase production,<sup>14</sup> and amino acid utilization<sup>15, 16</sup> allowed laboratorians to differentiate among the ever-growing list of bacteria responsible for infectious diseases.

Continued refinement of these diagnostic tests allowed for the development of rapid, or spot, testing for some compounds, resulting in quicker preliminary identification of enteric pathogens and common gram positive isolates.<sup>14, 17, 18</sup> Thus, by the middle of the 20<sup>th</sup> century the biochemical, growth-based approach became a well-defined and effective methodology inside the diagnostic laboratory. Through the utilization of various growth substrates incorporated into solid and liquid media, a unique metabolic pattern of an unknown microorganism could be established thereby providing a repeatable method for identification.

By 1965, the number of diagnostic tests utilized by the laboratory could range from five to over twenty depending on the type of bacterium isolated, the level of identification required (genus only or species), and the commonality of the organism.<sup>14, 19</sup> It became increasingly clear that the sheer volume of diagnostic tests, the increasing number of specimens submitted for identification and the amount of data accumulated would require medical microbiology laboratorians to develop more efficient methods and technologies to handle the growing demand.<sup>14, 20</sup>

### **Improved Efficiency through Computation and Miniaturization**

As the population continued to increase from the turn of the century through the 1960s,<sup>21</sup> so too did the demand for health care, hospital utilization and laboratory services.<sup>22-24</sup> It was not only the increase in quantity of specimens but a demand for better quality of service, primarily due to the growth of public and private insurance, which required diagnostic laboratories to adapt methodologies and practices for improving efficiency.<sup>24, 25</sup> These methodologies mainly occurred through two avenues: computer-assisted identification and streamlining of tests through miniaturization.

To aid the bacteriologist in identification, flow charts, dichotomous keys and diagnostic tables were usually consulted to guide one from preliminary through confirmatory testing. A step toward a more standardized process came in the form of cards containing a punched out hole for each biochemical test.<sup>19</sup> During the course of identification, the medical microbiologist would record their results by notching the holes for positive tests, then consult master cards obtained from reputable sources to match an identification. With the introduction of automatic data processing, the amount of physical material kept and time spent “looking up” an isolate were reduced, as were the errors associated with manually reading and matching results. Computing improved the accuracy of identification as well, once databases were updated for newer tests and organisms. Computing improved accuracy through the use of probabilities analysis (Bayesian theorem) which allowed for determining the statistically most probable isolate from a collection of established results.<sup>20, 26, 27</sup>

At the same time, laboratories and researchers were collectively working to standardize and streamline testing procedures in order to more consistently differentiate microorganisms so time was not wasted on repeat testing or misinterpretation.<sup>20</sup> Test miniaturization provided the next big improvement in laboratory efficiency in the form of multi-test kits. Until the 1970s, the



great bulk of required isolation and identification culture media was made in-house at each diagnostic laboratory, requiring significant time, materials, and storage space,<sup>19, 28</sup> as well as generating significant amounts of waste. Conventional plate- and tube-based testing, while versatile and effective for bacterial and yeast identification, could require approximately 8-20 tubes and take an average of 48 – 96 hours for complete interpretation after isolation, even for the more common aerobes and facultative anaerobes.<sup>14, 19, 24</sup> Depending on the number of specimens and organisms submitted, the laboratory could have hundreds of tubes resting in incubators at any given time, creating a logistical headache along with the tedium from manually inoculating and reading such a high volume of tubes.<sup>24</sup>

Some of the first steps toward the multi-test approach were conventional tube-based media containing two or more observable reactions (Table 1), such as Russell's double sugar, Kligler's iron, and triple sugar iron agars,<sup>8, 29</sup> and the use of paper discs or strips (PathoTec) impregnated with dried reagents.<sup>30, 31</sup> A two-tubed (R-B media) identification system for members of the Enterobacteriaceae was designed to allow simultaneous testing of up to eight biochemical reactions.<sup>32</sup> A significant development in testing efficiency came from the work of Hartman, Buissiere, and Nardon who established many of the physical and chemical requirements of a multi-test micromethod.<sup>33, 34</sup> The outcome of this work produced the Analytab system (API), a plastic strip containing 20 small capsules or micro-tubes, with each capsule containing a dehydrated biochemical substrate for testing metabolic usage.<sup>35</sup> From 1969 to 1979, a number of additional miniaturized multi-test kits appeared in medical laboratories, including the AuxoTab, Enterotube, Micro-Media, and Micro-ID systems.<sup>36, 37</sup> Despite differences in design, the number of tests carried out, and incubation times, all of the multi-test kits were based on adding a standardized inoculum to the system and observing for visible color changes in each

testing compartment after incubation. These color changes were produced either spontaneously or after the addition of reagents.<sup>36</sup>

The miniaturized multi-test approach brought many benefits and improvements to the diagnostic capabilities of the medical laboratory compared with conventional plate and tube-based identification. After the initial release of these systems, many underwent further refinement that improved both efficiency and accuracy. Ease of use and storage, readily disposable after use, accurate for identification, more economical in terms of data provided, and decreased time to identification were all advantages of this approach.<sup>35-38</sup> The API system became the prototype kit adopted in many laboratories due to its versatility in usage for many groups of bacteria (Figure 1).

Utilizing the API 20E system instead of conventional tube-based testing for members of the Enterobacteriaceae reduced by more than half the total cost per identification of an isolate, accomplished through a reduction in both labor and media.<sup>39</sup> For common gram-positive and gram-negative bacteria, the API gave  $\geq 90\%$  congruence with conventional biochemical testing methods, making it a reliable alternative.<sup>40-42</sup> Additionally, other kits were developed for the typically hard to grow and test species of *Streptococcus*, *Neisseria*, and *Haemophilus*. Subsequent development of rapid test kits allowed reproducible results obtained more quickly for testing of common anaerobes as well as other fastidious organisms, with a time to identification in the range of 4 – 48 hours.<sup>28, 43, 44</sup>

### **Maximizing Efficiency with Automation**

As the number of individuals seeking quality health care continued to rapidly increase, so too did the cost of providing required healthcare, driving the demand for quicker, more efficient and accurate microbiology diagnostic services.<sup>25, 45</sup> While utilizing multi-test kits provided many

advantages as previously outlined, there were still opportunities to improve upon the formula. Miniaturized kits required manual inoculation, addition of external reagents and interpretation of results, which were prone to inconsistencies and errors, requiring further time to complete. The API 20E system required at least three minutes to inoculate and ten minutes to interpret after incubation per test;<sup>36, 38</sup> kits providing more tests could take even longer. When only a few samples are involved this time requirement is fairly insignificant. However, inoculating and reading 50 – 100 samples a day would require substantial labor and time in comparison.

Automatic data processors had demonstrated their efficiency and effectiveness for years and were now widely available to medical laboratories. It now became possible to explore the utility of automation in bulk microbial identification. The AutoMicrobic System (Vitek), born out of a National Aeronautics and Space Administration (NASA) initiative to identify microorganisms in a spacecraft environment, was subsequently modified in 1973 to identify clinical isolates directly from urine specimens.<sup>46</sup> While successful identification rates were high, it was not cost effective to run every specimen directly through the system without isolation and screening procedures to eliminate unnecessary reagent waste and technician time.<sup>47</sup> This system was further modified to run identification tests from a standardized inoculum containing one organism. From the late 1970s through the early 2000s, additional automated and semi-automated systems based on metabolic and enzymatic analyses were developed and further refined including, but not limited to, MicroScan, Phoenix, Sensititre and Vitek systems (Table 1), each with their own custom substrate cartridge, kit, panel, or plate for testing.<sup>48-50</sup>

Fully automated instruments are responsible for the majority of specimen identification in hospitals today. They can vary slightly or considerably from one another in their degree of automation, spectrum of organisms identified, method of inoculation, sample capacity, and

turnaround time.<sup>51-53</sup> Automated instruments use turbidometric, colorimetric and/or fluorimetric principles for quicker, and usually, more statistically confident identification of isolates compared with any manual, kit-based method.<sup>50, 51, 54</sup> More so, automated methods, regardless of the particular instrument used, have increased the total number (>200) of clinical isolates that can be inoculated, incubated, and identified within the span of 24 hours. Thus, laboratory productivity is increased without sacrificing quality of results.<sup>52, 54, 55</sup> An equally, if not more, significant advancement with automated biochemical systems over their manual counterparts is the ability to simultaneously determine an unknown isolate's identification and antimicrobial susceptibility patterns in the same device under the same condition (Figure 2).

With the widespread use of antibiotics and the concurrent observation of antimicrobial resistance, the need to conduct antimicrobial susceptibility testing (AST) became a necessity. AST was initially developed and standardized through the Kirby-Bauer<sup>56, 57</sup>, or disk diffusion, method. Standardized macro- and micro-dilution methods for minimum inhibitory concentration (MIC) determination occurred in the late 1970s.<sup>58</sup> Before automated instrumentation became widely available, all AST was accomplished manually and separately from the identification of an isolate (Figure 1), requiring additional materials and added time, both in set-up and in obtaining results: minimum of 18 – 24 hours compared with as little as 3.5 – 18 hours.<sup>59, 60</sup> The decrease in turnaround time, for both identification and antimicrobial susceptibility determination, ultimately led to a shorter length of stay for patients (~ one day shorter) and decreased mortality rates, resulting in substantial cost savings through a reduction in additional laboratory tests and performance of fewer invasive procedures.<sup>60, 61</sup> Today's automated instruments come with extensive databases and analytics software that allow further scrutiny of AST results for detection of resistance and atypical patterns, while providing the ability to

communicate information faster with pharmacy personnel to deliver real-time adjustments to patient care.<sup>62, 63</sup>

Currently, automated and semi-automated biochemical testing are the most widely utilized approach to microbial identification and antimicrobial susceptibility determination for the majority of bacterial and yeast isolates.<sup>64</sup> Additionally, automated modular machines, including Kiestra and WASP, have been developed to handle the processing, inoculation, and incubation of bulk, routine specimens such as urine and swabs, as well as providing growth imaging and isolate selection.<sup>65</sup> Nevertheless, automated technologies have not simply replaced all prior biochemical methodologies, regardless of laboratory capacity.

Prepackaged, multi-test kits and tube-based media are still routinely used for fastidious, hard-to-grow and rarely encountered organisms including viridians streptococci, species of *Neisseria* and *Haemophilus*, some non-fermenting gram-negative rods, *Vibrio* species, mycobacteria, and anaerobes which may not be identified accurately, or in many cases unable to be identified, with automated methods.<sup>44, 52, 55, 66-68</sup> Other, non-metabolic based methods, such as serology and molecular, have provided additional approaches to microbial identification without the need for isolation and growth of problematic organisms. Moreover, determining the antimicrobial susceptibility patterns of these same microorganisms, when necessary, requires non-automated methods as well, such as disk diffusion and Etest (bioMerieux), for accurate results.<sup>63</sup>

### **A New Paradigm in Culture-Based Testing**

With growth-based biochemical methods handling the bulk identification of common bacteria and yeast, can we expect any further advancement in application and instrumentation within this approach? The development of chromogenic media, refinement of testing panels,

improved optics, and more robust software analytics have provided some increase in efficiency and accuracy in recent years.<sup>68, 69</sup> While it is hard to anticipate future innovation, it is unlikely that we will see such significant improvement of current biochemical diagnostic techniques as have occurred with the transition from tube-based testing, to miniaturized test kits, and finally to full-scale automation. The limiting factor here is the dependency on microbial growth and substrate utilization for identification. Use of mass spectrometry for the identification of pathogenic bacteria (Table 1), first described in 1975, represents a unique phenotypic approach which has recently become a very practical method for speciation of a wide array of microorganisms in the clinical setting.<sup>70-73</sup>

Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) is not a traditional biochemical technique; organisms are not grown with various substrates to determine metabolic usage and specific enzyme production is not detected. Best described as an analytical chemistry identification method, MALDI-TOF determines an organism's protein "fingerprint" by bombarding a single colony with a high-energy laser to produce individual peptide fragments which vary in size, yielding a unique chemical spectrum.<sup>74</sup> It is not the first non-utilization-based method used for identification; gas and liquid chromatography techniques were developed in the 1980s and 1990s to identify bacteria and yeast based on their cellular composition.<sup>51, 64, 75</sup> However, MALDI-TOF is a true departure from any other phenotypic approach in its functional, efficient and accurate application to nearly all groups of microorganisms.<sup>76</sup> This approach has shown to consistently perform, at the very least, as well as automated biochemical methods, though usually better.<sup>77</sup> Indeed, mass spectrometry is the most likely technique to completely replace current automated, growth-based systems for routine identification of isolates, as has already occurred within many diagnostics laboratories (Figure

3). This includes for the identification of rarely encountered, fastidious and slow-growing organisms such as species of *Campylobacter* and *Helicobacter*,<sup>78</sup> *Legionella*,<sup>79</sup> *Mycobacterium*,<sup>80, 81</sup> anaerobes,<sup>82</sup> non-fermenting bacteria,<sup>83, 84</sup> yeasts<sup>85, 86</sup> and filamentous fungi.<sup>87, 88</sup>

The capability to accurately and precisely identify bacteria and fungi at an extremely low cost-per-sample analysis is yet another advantage of the mass spectrometric approach (Figure 4). Long and short-term studies have shown significant reductions in costs when comparing conventional and automated approaches with MALDI-TOF MS.<sup>73, 76, 85</sup> One 11 year study demonstrated a five-fold and a nearly 100-fold reduction in the average cost-per-test compared with current phenotypic and gene sequencing methods, respectively.<sup>83</sup> Other studies have supported these findings, revealing an approximate cost of \$0.50 - \$2.00 for each identification, depending on the specific instrument used and the type of isolate.<sup>73, 89, 90</sup> The initial cost of a MALDI-TOF MS instrument can be a limitation for smaller laboratories with a price range of \$180,000 – \$200,000;<sup>89</sup> however, the savings from lower operating and labor costs and a reduction in repeat testing, subculture media and waste can offset the initial cost within one year depending on the number of samples routinely analyzed.<sup>77, 91</sup>

Without the need for microbial growth after isolation, time-to-result (TTR) is greatly reduced compared with conventional methods as well (Figure 4), with the majority of identification results (87 – 93%) obtained 12 – 24 hours after receipt of the initial specimen.<sup>91, 92</sup> Once a sample is placed on the instrument, identification typically occurs within 5 – 10 minutes depending on the organism type.<sup>74, 89, 92</sup> The cost- and time-saving advantages of using MALDI-TOF MS are most pronounced for the workup and identification of slow-growing bacteria,

specifically anaerobes and mycobacteria, where a result may be obtained within minutes after isolation instead of days or weeks.

Limitations of MALDI-TOF MS in identifying some organisms are largely due to a lack of sufficient reference spectra in databases.<sup>64, 83</sup> Currently, databases are proprietary, unlike databases of genetic sequence, so they require manufacturer updates to enhance detection limits.<sup>64</sup> Laboratories may build their own in-house databases to further improve the instruments capabilities, though the quality of spectra obtained must be ensured through molecular means to prevent spreading of erroneous data.<sup>77, 89</sup> Some organisms, such as *E. coli* and *Shigella* species, may not be reliably identified owing to nearly identical genetic profiles, and thus, nearly identical protein fingerprints. Human error, inadequate training, culture conditions and media composition are also sources of potential result variability with MALDI-TOF, as the current iterations of this technique require specific pre-analytical techniques depending on the type of microorganism being tested. Additionally, laboratories currently using MALDI-TOF MS as the primary method of identification must still rely on automated biochemical instruments and manual methods for determining antimicrobial susceptibilities.

### **Future Applications and Prospects**

The requirement to first isolate an infectious agent from a clinical sample is always required with any current biochemical and growth-based approach, including mass spectrometry in its current state. As such there is still some inherent risk when handling select agents and some organisms which cannot be isolated, or are very difficult to do so, still require other means of testing.<sup>89</sup> Serological and molecular techniques provide the means to test for organisms directly from specimens, thereby providing a potentially quicker identification while avoiding the



inherent difficulties and risks of isolating and growing especially dangerous or fastidious microbes.

Nevertheless, MALDI-TOF MS has been shown to reliably identify organisms directly from some clinical specimens, including blood and urine, while other specimen types are currently being investigated.<sup>89, 93</sup> Likewise, there is potential for MALDI-TOF MS to differentiate individual strains of microorganisms, as well as detect antimicrobial resistance and resistant mechanisms, including  $\beta$ -lactamase and carbapenemase production, and detection of MRSA protein-specific spectra.<sup>94, 95</sup> It is also possible to apply the mass spectrometric approach to other biomolecules, such as base nucleotides, to produce new methodologies like polymerase chain reaction electrospray ionization mass spectrometry (PCR/ESI-MS).<sup>96</sup> This hybrid technique combines the speed and utility of MALDI-TOF MS with the sensitivity and specificity of PCR amplification. Future advancements and applications will likely focus on incorporating these existing technologies into a fully integrated and automated system, from processing, incubation, isolation, to identification, so as to reach maximum operational efficiency by further reducing costs and turnaround time. Further work is necessary to improve the efficiency and practicality of these particular MALDI-TOF MS applications in order for them to be adopted for routine clinical usage.

## **Conclusions**

The biochemical and growth-based approaches in the diagnostic laboratory were initially born out of the discovery of microorganisms and the need to confirm their causative link to infectious disease. As the need and requirement for quality healthcare became commonplace, laboratories improved diagnostic capabilities and increased testing capacity, without sacrificing quality of results, by first utilizing miniaturized, multi-test kits followed by computer automation

for the routine identification of clinical isolates. From its initial inception in the late 1800s to within just a few years ago, growth-based, biochemical identification methods have been the de facto method of choice for hospital-based microbiology laboratories. Now, we have entered a new era of diagnostic testing where the routine approach is based not on what an organism's proteins do, but by the proteins themselves.

A laboratory's capacity to adopt new methodologies and technologies is dependent on many factors though, and newer approaches such as MALDI-TOF will not, and cannot, be utilized by every microbiology department, as it may not be cost effective or practical for smaller capacity hospitals. However, with the continual increase in cost of and demand for healthcare services coupled with the level of accuracy and efficiency offered by MALDI and other newer techniques, more and more laboratories will make the change. As diagnostic laboratories continue to consolidate into fewer, but larger, testing facilities embracing full-scale automation, traditional approaches and methods will continue to be replaced.<sup>97</sup> While medical laboratory technicians and scientists have always needed to acquire new skills and knowledge to use new methods and tools as they become available, the underlying principle behind these techniques has remained relatively unchanged until very recently. It is becoming more likely that the instilled art and practice of memorizing and reading biochemical growth patterns will no longer be required of the diagnostic microbiologist.

Table 1. Summary of biochemical approaches and techniques discussed.

Approach	Isolation Required	Growth Required for ID	Examples	Description of Approach
----------	--------------------	------------------------	----------	-------------------------

Abbreviations: API, analytical profile index; AST, antimicrobial susceptibility testing; ID, identification; MALDI, matrix-assisted laser-desorption ionization; MS, mass spectrometry.

Single Tube Tests	Yes	Yes	Christensen's urea agar, Simmons' citrate medium	Each tube needed requires inoculation, one reaction per tube, may need 8 – 20 different tubes for identification
Multi-Test Tube Systems	Yes	Yes	Durham tube, Kligler's iron agar, Triple sugar iron agar, R-B media	One inoculation per system, more than one reaction possible in each tube
Rapid (Spot) Tests	Yes	No	Catalase, Oxidase, Indole production	Individual colony mixed with a reagent, reaction develops within seconds, based on preformed enzyme
Multi-test Kits	Yes	Yes	PathoTec, API, AuxoTab, Enterotube, Micro-Media	Manual inoculation of trips or tubes containing small compartments of media, able to test for $\geq 8$ reactions in each kit
Automated Growth-Based Systems	Yes	Yes	Vitek, MicroScan, Phoenix, Sensititre	Single inoculum device loaded onto small-to-large capacity machines, capable of ID and AST at the same time
Mass Spectrometry	Yes/No	No	Vitek MS, MALDI Biotyper	Single colony inoculated on plate, laser fragments cell into peptidic fragments, AST on separate automated instrument




Figure 1: Scheme for the identification and antimicrobial susceptibility testing of a clinical isolate using a miniaturized test kit approach.




Figure 2: Scheme for the identification and antimicrobial susceptibility testing of a clinical isolate using a standard automated, biochemical approach.




Figure 3: Scheme for the identification and antimicrobial susceptibility testing of a clinical isolate using the MALDI-TOF approach.




Figure 4: Qualitative comparison of biochemical and growth-based approaches to identification.

Cost per test includes materials and labor as estimated by studies cited and discussed in the text.



## **Acknowledgements**

I would like to thank my fellow focus series authors for their input concerning this manuscript. I would also like to thank an anonymous reviewer for their comments and suggestions which made this a better paper.

## References

1. Carter KC. Koch's postulates in relation to the work of Jacob Henle and Edwin Klebs. *Medical History*. 1985;29(4):353-74.
2. Muir R. *Manual of bacteriology*: YJ Pentland; 1899.
3. Loeb L. The influence of certain bacteria on the coagulation of the blood. *The Journal of medical research*. 1903;10(3):407.
4. MacConkey A. Lactose-Fermenting Bacteria in Faeces. *Journal of Hygiene*. 1905;5(3):333-79.
5. Willson HS. The Isolation of *B. Typhosus* from Infected Water, with Notes on a New Process. *Epidemiology and Infection*. 1905;5(4):429-43.
6. Winslow CE, Kligler IJ, Rothberg W. Studies on the Classification of the Colon-Typhoid Group of Bacteria with Special Reference to their Fermentative Reactions. *Journal of bacteriology*. 1919;4(5):429-503.
7. Durham HE. A simple method for demonstrating the production of gas by bacteria. *British medical journal*. 1898;1(1952):1387.
8. Sulkin SE, Willett JC. A triple sugar-ferrous sulfate medium for use in identification of enteric organisms. *The Journal of Laboratory and Clinical Medicine*. 1940;25(6):649-53.
9. Clark WM, Lubs HA. The differentiation of bacteria of the colon-aerogenes family by the use of indicators. *J infect Dis*. 1915;17(1):160-73.
10. Simmons JS. A Culture Medium for Differentiating Organisms of Typhoid-Colon Aerogenes Groups and for Isolation of Certain Fungi. *The Journal of Infectious Diseases*. 1926;39(3):209-14.
11. Christensen WB. Urea decomposition as a means of differentiating *Proteus* and paracolon cultures from each other and from *Salmonella* and *Shigella* types. *Journal of Bacteriology*. 1946;52(4):461.
12. Zobell C. Factors influencing the reduction of nitrates and nitrites by bacteria in semisolid media. *Journal of bacteriology*. 1932;24(4):273.
13. Kovacs N. A simplified method for detection indol formation by bacteria. *Immunities Forest*. 1928;26:311.
14. Steel K. Microbial identification. *Microbiology*. 1965;40(1):143-8.
15. Henriksen SD, Closs K. The production of phenylpyruvic acid by bacteria. *Acta Pathologica Microbiologica Scandinavica*. 1938;15(1):101-13.
16. Møller V. Simplified Tests for Some Amino Acid Decarboxylases and for the Arginine Dihydrolase System. 1955;36(2):158-72.
17. Disalvo JW. Desoxyribonuclease and Coagulase Activity of Micrococci. *Medical Technicians Bulletin*. 1958;9(5):191-6.
18. Ljutov V. Technique of Indole Test. *Acta Pathologica et Microbiologica Scandinavica*. 1959;46(4):349-60.
19. Cowan ST, Steel KJ. *Manual for the identification of medical bacteria*: Cambridge: University Press.; 1965. x + 217 pp. p.
20. Rypka EW, Clapper WE, Bowen IG, Babb R. A Model for the Identification of Bacteria. *Microbiology*. 1967;46(3):407-24.
21. Drake DF, Raske KE. The changing hospital economy. *Hospitals*. 1974;48(22):34.
22. Arestad FH. Hospital Service in the United States: Twenty-Fifth Annual Presentation of Hospital Data by the Council on Medical Education and Hospitals of the American Medical Association. *Journal of the American Medical Association*. 1946;130(16):1073-161.
23. Andersen R, Hull JT. Hospital utilization and cost trends in Canada and the United States. *Health services research*. 1969;4(3):198-222.
24. Steel K, editor *The practice of bacterial identification*. Symp Soc Gen Microbiol; 1962.

25. Feldstein M. Quality Change and the Demand for Hospital Care. *Econometrica*. 1977;45(7):1681-702.
26. Friedman RB, Bruce D, MacLowry J, Brenner V. Computer-assisted Identification of Bacteria. *American Journal of Clinical Pathology*. 1973;60(3):395-403.
27. Lapage SP, Bascomb S, Willcox WR, Curtis MA. Identification of Bacteria by Computer: General Aspects and Perspectives. *Microbiology*. 1973;77(2):273-90.
28. Moore HB, Sutter VL, Finegold SM. Comparison of three procedures for biochemical testing of anaerobic bacteria. 1975;1(1):15-24.
29. Russell FF. The Isolation of Typhoid Bacilli from Urine and Feces with the Description of a new Double Sugar Tube Medium. *The Journal of medical research*. 1911;25(1):217-29.
30. Matsen JM, Sherris JC. Comparative Study of the Efficacy of Seven Paper-Reagent Strips and Conventional Biochemical Tests in Identifying Gram-negative Organisms. 1969;18(3):452-7.
31. Snyder M, Donnelly D, Nix M. On some practical applications of impregnated, dried paper discs containing various reagents for the cultural differentiation of bacteria. *The American journal of medical technology*. 1951;17(3):105-11.
32. Kohn J, editor A 2-Tube Technique for the Identification of Organisms of the Enterobacteriaceae Group. *Journal of Pathology and Bacteriology*; 1954: John Wiley & Sons Ltd Baffins Lane Chichester, W Sussex PO19 1UD, England.
33. Buisnière J, Nardon P. Nardon P. Microméthode d'identification des bactéries. I. Intérêt de la quantification des caractères biochimiques. *Ann Inst Pasteur (Paris)*. 1968;115(2):218-31.
34. Hartman PA. Miniaturized microbiological methods. *Advances in Applied Microbiology*. 1968.
35. Washington JA, Yu PKW, Martin WJ. Evaluation of Accuracy of Multitest Micromethod System for Identification of Enterobacteriaceae. 1971;22(3):267-9.
36. Nord C-E, Lindberg AA, Dahlbäck AJMM, Immunology. Evaluation of five test-kits —API, AuxoTab, Enterotube, PathoTec and R/B— for identification of Enterobacteriaceae. 1974;159(3):211-20.
37. Kelly MT, Latimer JM. Comparison of the automicrobic system with API, enterotube, micro-ID, micro-media systems, and conventional methods for identification of Enterobacteriaceae. 1980;12(5):659-62.
38. Smith P, Tomfohrde K, Rhoden D, Balows A. API system: a multitube micromethod for identification of Enterobacteriaceae. 1972;24(3):449.
39. Bartlett RC, Kohan TS, Rutz C. Comparative Costs of Microbial Identification Employing Conventional and Prepackaged Commercial Systems. *American Journal of Clinical Pathology*. 1979;71(2):194-200.
40. Kloos W, Wolfshohl J. Identification of Staphylococcus species with the API STAPH-IDENT system. *Journal of clinical microbiology*. 1982;16(3):509-16.
41. Shayegani M, Maupin PS, McGlynn DM. Evaluation of the API 20E system for identification of nonfermentative Gram-negative bacteria. 1978;7(6):539-45.
42. Freney J, Duperron M, Courtier C, Hansen W, Allard F, Boeufgras J, et al. Evaluation of API Coryne in comparison with conventional methods for identifying coryneform bacteria. *Journal of clinical microbiology*. 1991;29(1):38-41.
43. Murray PR, Weber CJ, Niles A. Comparative evaluation of three identification systems for anaerobes. *Journal of clinical microbiology*. 1985;22(1):52-5.
44. Barbé G, Babolat M, Boeufgras J, Monget D, Freney J. Evaluation of API NH, a new 2-hour system for identification of Neisseria and Haemophilus species and Moraxella catarrhalis in a routine clinical laboratory. *Journal of clinical microbiology*. 1994;32(1):187-9.
45. Waldo DR, Lazenby HC. Demographic characteristics and health care use and expenditures by the aged in the United States: 1977-1984. *Health care financing review*. 1984;6(1):1-29.

46. Aldridge C, Jones PW, Gibson S, Lanham J, Meyer M, Vannest R, et al. Automated Microbiological Detection/Identification System. 1977;6(4):406-13.
47. Hamoudi AC, Lin S. Cost analysis of the Auto Microbic system urine identification card. 1981;14(4):411-4.
48. Staneck JL, Vincelette J, Lamothe F, Polk EA. Evaluation of the Sensititre system for identification of Enterobacteriaceae. 1983;17(4):647-54.
49. Hussain Z, Stoakes L, Stevens D, Schieven B, Lannigan R, Jones C. Comparison of the MicroScan system with the API Staph-Ident system for species identification of coagulase-negative staphylococci. *Journal of clinical microbiology*. 1986;23(1):126-8.
50. Truant AL, Starr E, Nevel CA, Tsolakis M, Fiss EF. Comparison of AMS-Vitek, microScan, and autobac series II for the identification of gram-negative bacilli. *Diagnostic Microbiology and Infectious Disease*. 1989;12(3):211-5.
51. Stager CE, Davis JR. Automated systems for identification of microorganisms. 1992;5(3):302-27.
52. Jin W-Y, Jang S-J, Lee M-J, Park G, Kim M-J, Kook J-K, et al. Evaluation of VITEK 2, MicroScan, and Phoenix for identification of clinical isolates and reference strains. *Diagnostic microbiology and infectious disease*. 2011;70(4):442-7.
53. O'Hara CM, Tenover FC, Miller JM. Parallel comparison of accuracy of API 20E, Vitek GNI, MicroScan Walk/Away Rapid ID, and Becton Dickinson Cobas Micro ID-E/NF for identification of members of the family Enterobacteriaceae and common gram-negative, non-glucose-fermenting bacilli. 1993;31(12):3165-9.
54. Eigner U, Schmid A, Wild U, Bertsch D, Fahr A-M. Analysis of the comparative workflow and performance characteristics of the VITEK 2 and Phoenix systems. *Journal of clinical microbiology*. 2005;43(8):3829-34.
55. Sellenriek P, Holmes J, Ferrett R, Drury R, Storch GA, editors. Comparison of MicroScan Walk-Away®, Phoenix™ and VITEK-TWO® Microbiology systems used in the identification and susceptibility testing of bacteria. Abstr 105th General Meeting of the American Society for Microbiology; 2005: Citeseer.
56. Bauer A, Kirby W, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. *American journal of clinical pathology*. 1966;45(4\_ts):493-6.
57. Biemer JJ. Antimicrobial susceptibility testing by the Kirby-Bauer disc diffusion method. *Annals of Clinical & Laboratory Science*. 1973;3(2):135-40.
58. Stratton CW, Reller LB. Serum Dilution Test for Bactericidal Activity. II. Standardization and Correlation with Antimicrobial Assays and Susceptibility Tests. *The Journal of Infectious Diseases*. 1977;136(2):196-204.
59. Jorgensen JH. Selection criteria for an antimicrobial susceptibility testing system. *Journal of clinical microbiology*. 1993;31(11):2841-4.
60. Barenfanger J, Drake C, Kacich G. Clinical and Financial Benefits of Rapid Bacterial Identification and Antimicrobial Susceptibility Testing. 1999;37(5):1415-8.
61. Doern GV, Vautour R, Gaudet M, Levy B. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. *Journal of clinical microbiology*. 1994;32(7):1757-62.
62. James HJ, Mary Jane F. Antimicrobial Susceptibility Testing: General Principles and Contemporary Practices. *Clinical Infectious Diseases*. 1998;26(4):973-80.
63. Reller LB, Weinstein M, Jorgensen JH, Ferraro MJ. Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices. *Clinical Infectious Diseases*. 2009;49(11):1749-55.
64. Carroll KC, Patel R. Systems for Identification of Bacteria and Fungi. *Manual of Clinical Microbiology*. 12015. p. 29-43.

65. Iversen J, Stendal G, Gerdes CM, Meyer CH, Andersen CØ, Frimodt-Møller N. Comparative evaluation of inoculation of urine samples with the Copan WASP and BD Kiestra Inoqula instruments. *Journal of clinical microbiology*. 2016;54(2):328-32.
66. Summanen P, Jousimies-Somer H. Comparative evaluation of RapID ANA and API 20A for identification of anaerobic bacteria. *European Journal of Clinical Microbiology and Infectious Diseases*. 1988;7(6):771-5.
67. O'Hara CM, Sowers EG, Bopp CA, Duda SB, Strockbine NA. Accuracy of six commercially available systems for identification of members of the family Vibrionaceae. *Journal of clinical microbiology*. 2003;41(12):5654-9.
68. Chatzigeorgiou K-S, Sergentanis TN, Tsiodras S, Hamodrakas SJ, Bagos PG. Phoenix 100 versus Vitek 2 in the identification of gram-positive and gram-negative bacteria: a comprehensive meta-analysis. *Journal of clinical microbiology*. 2011;49(9):3284-91.
69. Perry JD, Freydière AM. The application of chromogenic media in clinical microbiology. 2007;103(6):2046-55.
70. Anhalt JP, Fenselau C. Identification of bacteria using mass spectrometry. *Analytical Chemistry*. 1975;47(2):219-25.
71. Krishnamurthy T, Ross PL. Rapid Identification of Bacteria by Direct Matrix-assisted Laser Desorption/Ionization Mass Spectrometric Analysis of Whole Cells. *Rapid Communications in Mass Spectrometry*. 1996;10(15):1992-6.
72. Claydon MA, Davey SN, Edwards-Jones V, Gordon DB. The rapid identification of intact microorganisms using mass spectrometry. *Nature Biotechnology*. 1996;14(11):1584-6.
73. Seng P, Drancourt M, Gouriet F, La Scola B, Fournier P-E, Rolain JM, et al. Ongoing Revolution in Bacteriology: Routine Identification of Bacteria by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry. *Clinical Infectious Diseases*. 2009;49(4):543-51.
74. Maier T, Klepel S, Renner U, Kostrzewa M. Fast and reliable MALDI-TOF MS-based microorganism identification. *Nature Methods*. 2006;3:328.
75. Thibert L, Lapiere S. Routine application of high-performance liquid chromatography for identification of mycobacteria. 1993;31(7):1759-63.
76. Neville SA, LeCordier A, Ziochos H, Chater MJ, Gosbell IB, Maley MW, et al. Utility of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry following Introduction for Routine Laboratory Bacterial Identification. 2011;49(8):2980-4.
77. Patel R. MALDI-TOF MS for the diagnosis of infectious diseases. *Clinical chemistry*. 2015;61(1):100-11.
78. Martiny D, Dediste A, Debruyne L, Vlaes L, Haddou NB, Vandamme P, et al. Accuracy of the API Campy system, the Vitek 2 Neisseria–Haemophilus card and matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the identification of Campylobacter and related organisms. *Clinical microbiology and infection*. 2011;17(7):1001-6.
79. Moliner C, Ginevra C, Jarraud S, Flaudrops C, Bedotto M, Couderc C, et al. Rapid identification of Legionella species by mass spectrometry. 2010;59(3):273-84.
80. Pignone M, Greth KM, Cooper J, Emerson D, Tang J. Identification of mycobacteria by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. *Journal of clinical microbiology*. 2006;44(6):1963-70.
81. Biswas S, Rolain J-M. Use of MALDI-TOF mass spectrometry for identification of bacteria that are difficult to culture. *Journal of microbiological methods*. 2013;92(1):14-24.
82. Barreau M, Pagnier I, La Scola B. Improving the identification of anaerobes in the clinical microbiology laboratory through MALDI-TOF mass spectrometry. *Anaerobe*. 2013;22:123-5.

83. Seng P, Abat C, Rolain JM, Colson P, Lagier J-C, Gouriet F, et al. Identification of Rare Pathogenic Bacteria in a Clinical Microbiology Laboratory: Impact of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry. 2013;51(7):2182-94.
84. Degand N, Carbonnelle E, Dauphin B, Beretti J-L, Le Bourgeois M, Sermet-Gaudelus I, et al. Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Nonfermenting Gram-Negative Bacilli Isolated from Cystic Fibrosis Patients. 2008;46(10):3361-7.
85. Dhiman N, Hall L, Wohlfiel SL, Buckwalter SP, Wengenack NL. Performance and cost analysis of matrix-assisted laser desorption ionization–time of flight mass spectrometry for routine identification of yeast. *Journal of clinical microbiology*. 2011;49(4):1614-6.
86. Westblade LF, Jennemann R, Branda JA, Bythrow M, Ferraro MJ, Garner OB, et al. Multicenter study evaluating the Vitek MS system for identification of medically important yeasts. *Journal of clinical microbiology*. 2013;51(7):2267-72.
87. De Carolis E, Posteraro B, Lass-Flörl C, Vella A, Florio A, Torelli R, et al. Species identification of *Aspergillus*, *Fusarium* and *Mucorales* with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *Clinical microbiology and infection*. 2012;18(5):475-84.
88. Iriart X, Lavergne R-A, Fillaux J, Valentin A, Magnaval J-F, Berry A, et al. Routine identification of medical fungi by the new Vitek MS matrix-assisted laser desorption ionization–time of flight system with a new time-effective strategy. *Journal of clinical microbiology*. 2012;50(6):2107-10.
89. Wieser A, Schneider L, Jung J, Schubert S. MALDI-TOF MS in microbiological diagnostics—identification of microorganisms and beyond (mini review). *Applied Microbiology Biotechnology*. 2012;93(3):965-74.
90. Cherkaoui A, Hibbs J, Emonet S, Tangomo M, Girard M, Francois P, et al. Comparison of Two Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Methods with Conventional Phenotypic Identification for Routine Identification of Bacteria to the Species Level. 2010;48(4):1169-75.
91. Gaillot O, Blondiaux N, Loiez C, Wallet F, Lemaître N, Herwegh S, et al. Cost-effectiveness of switch to matrix-assisted laser desorption ionization-time of flight mass spectrometry for routine bacterial identification. *Journal of clinical microbiology*. 2011;49(12):4412-.
92. Tan KE, Ellis BC, Lee R, Stamper PD, Zhang SX, Carroll KC. Prospective Evaluation of a Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry System in a Hospital Clinical Microbiology Laboratory for Identification of Bacteria and Yeasts: a Bench-by-Bench Study for Assessing the Impact on Time to Identification and Cost-Effectiveness. 2012;50(10):3301-8.
93. Carbonnelle E, Mesquita C, Bille E, Day N, Dauphin B, Beretti J-L, et al. MALDI-TOF mass spectrometry tools for bacterial identification in clinical microbiology laboratory. *Clinical Biochemistry*. 2011;44(1):104-9.
94. Sandrin TR, Goldstein JE, Schumaker S. MALDI TOF MS profiling of bacteria at the strain level: A review. 2013;32(3):188-217.
95. Oviaño M, Bou G. Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for the Rapid Detection of Antimicrobial Resistance Mechanisms and Beyond. 2018;32(1):e00037-18.
96. Baldwin CD, Howe GB, Sampath R, Blyn LB, Matthews H, Harpin V, et al. Usefulness of multilocus polymerase chain reaction followed by electrospray ionization mass spectrometry to identify a diverse panel of bacterial isolates. *Diagnostic microbiology and infectious disease*. 2009;63(4):403-8.

97. Bourbeau PP, Ledebor NA. Automation in Clinical Microbiology. *Journal of clinical microbiology*. 2013;51(6):1658-65.





